CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions

Hsiang Wei Kuo, Shu Chih Liu, Hsiao Hui Tsou, Sheng Wen Liu, Keh Ming Lin, Shao Chun Lu, Mei Chun Hsiao, Chin Fu Hsiao, Chia Yih Liu, Chia Hui Chen, Mong Liang Lu, Winston W. Shen, Hwa Sheng Tang, Shen Ing Liu, Liang Huey Chang, Hsiao Yu Wu, Yao Sheng Chang, Teng Kuang Yeh, Andrew Ch Chen, Yu Li Liu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim: The liver CYP1A2 enzyme may metabolize antidepressant escitalopram (S-CIT) to S-desmethylcitalopram (S-DCIT) and S-didesmethylcitalopram (S-DDCIT). This study tested whether genetic polymorphisms in the CYP1A2 gene are associated with the treatment responses to S-CIT. Materials & methods: Ten SNPs in CYP1A2 were selected and genotyped in 158 patients under S-CIT treatment. The serum levels of S-CIT and its metabolites were measured by HPLC. Results:CYP1A2 SNPs rs2069521, rs2069526, rs4646425 and rs4646427 are significantly associated with the metabolic ratios of S-DDCIT/S-DCIT (p = 0.002, 0.018, 0.008 and 0.004, respectively) at week 2 of treatment. Carriers of the allele types associated with higher S-DDCIT/S-DCIT ratios had more severe side effects. Conclusion: These results suggest that genetic variants in CYP1A2 may be indicators for S-CIT metabolism and that the fast metabolizers may experience more severe adverse reactions in the early stages of S-CIT treatment. Original submitted 27 December 2012; Revision submitted 15 May 201.

Original languageEnglish
Pages (from-to)1191-1201
Number of pages11
JournalPharmacogenomics
Volume14
Issue number10
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • CYP1A2
  • escitalopram
  • major depressive disorder
  • side effects
  • SNP

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions'. Together they form a unique fingerprint.

  • Cite this

    Kuo, H. W., Liu, S. C., Tsou, H. H., Liu, S. W., Lin, K. M., Lu, S. C., Hsiao, M. C., Hsiao, C. F., Liu, C. Y., Chen, C. H., Lu, M. L., Shen, W. W., Tang, H. S., Liu, S. I., Chang, L. H., Wu, H. Y., Chang, Y. S., Yeh, T. K., Chen, A. C., & Liu, Y. L. (2013). CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 14(10), 1191-1201. https://doi.org/10.2217/pgs.13.105